Setterwalls assisted LIDDS when entering an R&D agreement with Johnson & Johnson

LIDDS has entered a agreement with one of the world’s largest pharmaceutical companies to develop an oncology product.

Setterwalls assisted the research company LIDDS AB (publ) when entering an agreement with the American pharmaceutical company Johnson & Johnson Enterprise Innovation Inc. to develop an oncology product based on LIDDS’ NanoZolid® technology. The agreement includes an option for an exclusive global product license.